Advanced non-invasive imaging biomarker for use in drug trials

在医疗保健领域，及时和个性化的干预措施对当前和未来各种疾病治疗的最终有效性至关重要。快速正确的诊断是解锁退行性疾病（如痴呆和其他神经退行性疾病）个性化方法的关键，其中分层是正确治疗的必要条件。这些疾病的早期检测将导致显著改善患者预后，但在这些适应症中缺乏诊断选择。AINOSTICS的技术代表了一项突破，将提供一个自动化，可扩展和个性化的医疗保健平台，用于使用多模态成像和非成像MRI数据辅助组织修饰疾病的临床诊断;对患者的治疗有用，重要的是，AINOSTICS的技术可以自动和智能地分析扫描，以提供灵敏和准确的微然后，将关于关键组织和器官结构的结构信息与来自健康人群的信息进行比较，以检测疾病的特征。我们希望AINOSTICS的软件成为临床实践和药物开发的常规部分，因为我们的智能分析结果将为临床医生，研究人员和成像中心提供方便，具有成本效益的手段，以获得可靠，定量和客观的诊断数据。对于严重的全球性疾病，AINOSTICS的技术有可能节省患者评估时间，加快临床路径，提高护理质量，改善患者预后，并为疾病修饰疗法的发展做出重要贡献。

In healthcare, timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. Rapid correct diagnosis is key in unlocking personalised approaches for degenerative diseases such as dementia and other neurodegenerative conditions, where stratification is mandatory for correct treatment. Early detection of these diseases would result in a significantly improved patient prognosis but there is a dearth of diagnostic options in these indications. AINOSTICS' technology represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis of tissue modifying diseases using multi-modal imaging and non-imaging MRI data; useful for both the treatment of patients, and importantly, in the development of novel therapeutics.AINOSTICS' technology can automatically and intelligently analyse scans to provide sensitive and accurate micro-structural information about key tissue and organ structures then compare this with information from healthy populations to detect the signatures of disease. We intend for AINOSTICS' software to become a routine part of clinical practice and drug development as the results of our intelligent analysis will provide clinicians, researchers, and imaging centres a convenient and cost-effective means to get reliable, quantitative and objective diagnostic data.For serious global diseases, AINOSTICS' technology has the potential to save time during patient assessments, accelerate clinical pathways, standardise the quality of care and improve patient outcomes in addition to making important contributions to the development of disease modifying therapeutics.